KRTX News and Press, Karuna Therapeutics Inc. From 12/28/23

2023-12-28 08:15:02 ET Canaccord Genuity analyst issues BUY recommendation for KRTX on December 28, 2023 08:35AM ET. The previous analyst recommendation was Buy. KRTX was trading at $317.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

NEW YORK, NY / ACCESSWIRE / December 27, 2023 / Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...

NEW YORK, NY / ACCESSWIRE / December 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Daseke, Inc. (NASDAQ:DSKE)'s sale ...

2023-12-26 16:30:02 ET H.C. Wainwright analyst issues NEUTRAL recommendation for KRTX on December 26, 2023 02:02PM ET. KRTX was trading at $317 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 -...

2023-12-26 11:28:36 ET More on GSK AbbVie Vs. GSK: Dual Dominance In Pharma GSK - Greenshoots In The Horizon Getting_Ahead_of_Respiratory_Diseases_Slides EU regulators recommend against renewing approval for GSK's Blenrep AbbVie, AstraZeneca targeted ...

2023-12-24 09:11:28 ET More on Bristol-Myers Squibb Company , Karuna Therapeutics, etc. Bristol-Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge Bristol Myers...

2023-12-23 16:10:30 ET Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion. Analyst shares his view on biotech stocks The all-cash transaction values each share...

2023-12-23 04:24:25 ET Summary Bristol Myers Squibb is resorting to larger M&A deals to drive new product sales and combat the challenges it faces with the loss of exclusivity of its top-selling drug Revlimid. The company's 2023 outlook is tough, with stagnation and a decline ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX) is one of today's top gainers. The company's shares have moved -1.24% on the day to $161.95. Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neur...

Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis, ...